Linerixibat: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Linerixibat. Educational only — not medical advice.
Labeled uses
LYNAVOY is indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients. Limitations of Use Avoid use of LYNAVOY in patients with decompensated cirrhosis or those with prior or active hepatic decompensation events (e.g. variceal hemorrhage, ascites, hepatic encephalopathy) [see Use in Specific Populations (8.7) , Clinical Pharmacology (12.3) ] .
Source: FDA labeling via NIH DailyMed (set c00317c8…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.